Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% – What’s Next?

Posted by George Bondi on Aug 14th, 2026

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) was down 6.5% during mid-day trading on Thursday . The stock traded as low as $9.80 and last traded at $9.86. 64,512 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 77,022 shares. The stock had previously closed at $10.54.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Turn Therapeutics to a “hold” rating in a report on Saturday, July 18th. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Finally, Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Get Our Latest Stock Analysis on Turn Therapeutics

Turn Therapeutics Trading Down 6.5%

The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23. The firm’s fifty day simple moving average is $7.95 and its 200-day simple moving average is $5.31. The stock has a market cap of $293.71 million and a P/E ratio of -34.00.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.03) EPS for the quarter. Equities research analysts expect that Turn Therapeutics Inc. will post -0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TTRX. Ieq Capital LLC bought a new stake in Turn Therapeutics during the second quarter valued at $1,660,000. Millennium Management LLC bought a new position in shares of Turn Therapeutics in the 4th quarter worth about $377,000. Wellington Shields & Co. LLC acquired a new position in shares of Turn Therapeutics in the 4th quarter valued at about $259,000. BlackRock Inc. acquired a new position in shares of Turn Therapeutics in the 2nd quarter valued at about $282,000. Finally, Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics during the 2nd quarter valued at about $242,000.

Turn Therapeutics Company Profile

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.